Bluebird Bio has pushed forward the conversation on how to make million-dollar treatments affordable for insurers, but biopharma and payers are ominously quiet about…
Digging into the sales forecasts for gene therapies shows just how low their penetration is expected to be. Could biopharma come to regret its high-price, low-volume…
Vantage publishes its annual look ahead to 2019, examining the trends and issues that will shape biopharma in the coming year.
Autolus leads winners in spite of scepticism over its CAR-T, and gene therapies disappoint.
The private UK group could steal the thunder of rivals like Spark, Uniqure and Biomarin.
Padua gambit seems to have worked as new gene therapy looks the equal of Pfizer/Spark Therapeutics.
Novartis's $4m price target for AVXS-101 fuels concerns that too many new gene therapies could overburden payers without a hard look at how they are financed.
Crunch time nears for oral semaglutide and Novo will find out if concizumab can cut it in a crowded haemophilia market.
Early data are due for Krystal Biotech’s epidermolysis bullosa project and Uniqure’s haemophilia B candidate.